Semaglutide Injectable Product
Semaglutide Injectable Product 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries、Obese、Spinal Cord Injuries、Type 2 Diabetes。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
17 项
全球在招研究
9 项
已进入 III/IV 期
19 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- University of Colorado, Denver
- Marzieh Salehi
- Nordsjaellands Hospital
- University College Dublin
- Jens D Hove, MD,PHD
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- GynOncTrials
- The University of Texas Health Science Center, Houston
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
丹麦、爱尔兰、美国、加拿大、Greece、Hungary、Portugal、Serbia、瑞典、中国、中国香港、Brazil
正在招募患者的 Semaglutide Injectable Product 研究
Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity
IV 期招募中丹麦NCT07136714Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV
不适用招募中爱尔兰NCT04174755Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure
II 期 / III 期招募中丹麦NCT06423599Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes
IV 期招募中美国NCT06706284Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide
II 期 / III 期招募中加拿大NCT06387199Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium
II 期招募中加拿大NCT06073184Repurposing Semaglutide for the Treatment of Cocaine Use Disorder
II 期招募中美国NCT07227948A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
III 期招募中美国GreeceHungaryPortugalNCT07745504GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)
II 期招募中中国中国香港NCT05356104Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder
II 期招募中丹麦NCT07523633Feasibility of Semaglutide in Advanced Lung Disease
I 期 / II 期招募中美国NCT05746039Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.
不适用招募中美国NCT05419726A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes
III 期招募中加拿大NCT06894784Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents
I 期招募中美国NCT06575738JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity
IV 期招募中加拿大NCT06852391Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome
III 期招募中美国NCT05819853Fibrosis Lessens After Metabolic Surgery
IV 期招募中美国Brazil加拿大芬兰NCT06374875
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。